Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A follow-up study of a population of schizophrenic patients treated with clozapine
Autore:
Bourin, M; Guitton, B; Dailly, E; Hery, P; Jolliet, P;
Indirizzi:
Fac Med Nantes, F-44035 Nantes, France Fac Med Nantes Nantes France F-44035 Med Nantes, F-44035 Nantes, France Hop St Jacques, SHUP, Clin Psychopharmacol Unit, Nantes, France Hop St Jacques Nantes France Clin Psychopharmacol Unit, Nantes, France
Titolo Testata:
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
fascicolo: 8, volume: 25, anno: 2001,
pagine: 1481 - 1495
SICI:
0278-5846(200111)25:8<1481:AFSOAP>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
WEIGHT-GAIN; CHLORPROMAZINE;
Keywords:
agranulocytosis; clozapine; neutropenia; schizophrenia;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Bourin, M Fac Med Nantes, JE 2029 Neurobiol Anxiete, F-44035 Nantes, France Fac Med Nantes JE 2029 Neurobiol Anxiete Nantes France F-44035
Citazione:
M. Bourin et al., "A follow-up study of a population of schizophrenic patients treated with clozapine", PROG NEUR-P, 25(8), 2001, pp. 1481-1495

Abstract

1. Clozapine is a dibenzodiazepine neuroleptic which presents the advantage of not having undesirable neurological side-effects. Its efficacy for thetreatment of the symptoms of schizophrenia is known, but the use of clozapine is limited to treatment-resistant schizophrenic patients as it induces agranulocytosis with a higher incidence than that of other neuroleptic drugs.2. The present study was designed in order to evaluate the benefit/risk ofchronic treatment. The analysis was performed using the files of schizophrenic patients. These patients were not stabilized by a classical neuroleptic treatment and/or presented individual secondary effects.3. Clozapine induced neutropenia and 1 case of agranulocytosis in 3 females. Analysis of leukocyte expression highlighted some premonitory symptoms in patients who presented neutropenia. The observation of 2 to 3 early successive peaks in leukocyte expression (between the third and tenth week of treatment) could be predictive of neutropenia in the 3 to 4 months of treatment.4. The patients who presented a lower leukocyte base-line following a peakhad a higher risk, of developing neutropenia. This might explain some lateaccidents beyond the first six months of treatment.5. The present study confirmed the advantages of clozapine treatment and demonstrated that the risk of neutropenia may be diminished by the detectionof premonitory symptoms and the early monitoring of patients at risk i.e. female patients and subjects with a lower leukocyte base-line.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 21:48:27